Associate Professor Lisa Horvath

Clinical Associate Professor, Staff Specialist Medical Oncologist
Medicine, Central Clinical School

Telephone +61 2 9515 7680
Fax +61 2 9519 1546

Map

Selected grants

2013

  • Biobanking Stakeholder Network (BSN) Pre-Operative Consent Project; Yip S, Hawkins N, Miller D, Horvath L, Kench J, Brown S; Cancer Institute New South Wales/Community of Practice.
  • Evaluating a shared care pathway intervention to reduce chemotherapy outpatients' unplanned presentations to hospital; White K, McKenzie H, Hayes L, Simpson J, Horvath L, Willcock S, Cox K, Fethney J; National Health and Medical Research Council (NHMRC)/Project Grants.

2012

  • GeneAtlas Personal Microarray System; Richardson D, Scolyer R, Stocker R, Weninger W, Black J, Allen D, Murray M, Mason R, Twigg S, King N, Horvath L, Lovicu F, Lee C, Halliday G, Lovejoy D, Joshua D, Sharland A, Roufogalis B, Hambly B, Morris B, Bao B, Bishop A, Hibbs D, Lane D, Zhou F, Hanrahan J, Dixon K, Rendina L, Byrne M, Naylor M, Cole N, Jansson P, Dong Q, Codd R, Payne R, Assinder S, Chadban S, Fraser S, McLennan S, Suryo Rahmanto A, Lai D, Yu Y, Ju Y, Buckland M, Kovacevic Z, Saletta F, Zreiqat H, Kalinowski D, Groundwater P, Simes R, Zhang D, Boyer M, Murphy C; National Health and Medical Research Council (NHMRC)/Equipment Grants.

2007

  • Pre-clinical development of DpT iron chelators for cancer treatment; Richardson D, Lovejoy D, Boyer M, Horvath L; Cancer Institute New South Wales/Research Grant.
  • Use of Proteomic Analyses to improve the management of colorectal cancer - the SCRIPT for CRC Projec; Chan C, Kohonen-Corish M, Robertson G, Clarke S, Baker M, Beale P, Christopherson R, Bokey E, Horvath L, Lin B, Hong A, Solomon M, Chapuis P, McKay M, Mark M; Cancer Institute New South Wales/Translational Program Grant.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Nagrial, A., Chang, D., Nguyen, N., Johns, A., Chantrill, L., Humphris, J., Chin, V., Samra, J., Gill, A., Pajic, M., Kench, J., et al (2014). Adjuvant chemotherapy in elderly patients with pancreatic cancer. British Journal of Cancer, 110(2), 313-319. [More Information]
  • Suttie, C., Hruby, G., Horvath, L., Thompson, J. (2014). Cardiac metastasis in Merkel cell carcinoma. Journal of Clinical Oncology, 32(13), e52-e53. [More Information]
  • Lin, H., Castillo, L., Mahon, K., Chiam, K., Lee, B., Nguyen, Q., Boyer, M., Stockler, M., Pavlakis, N., Marx, G., Gurney, H., Horvath, L., et al (2014). Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer. British Journal of Cancer, 110(10), 2462-2471. [More Information]
  • Sutherland, S., Pe Benito, R., Henshall, S., Horvath, L., Kench, J. (2014). Expression of phosphorylated-mTOR during the development of prostate cancer. The Prostate, 74(12), 1231-1239. [More Information]
  • Yip, P., Cooper, W., Kohonen-Corish, M., Lin, B., McCaughan, B., Boyer, M., Kench, J., Horvath, L. (2014). Phosphorylated Akt expression is a prognostic marker in early-stage non-small cell lung cancer. Journal of Clinical Pathology, 67(4), 333-340. [More Information]
  • Selth, L., Townley, S., Bert, A., Stricker, P., Sutherland, P., Horvath, L., Goodall, G., Butler, L., Tilley, W. (2013). Circulating microRNAs predict biochemical recurrence in prostate cancer patients. British Journal of Cancer, 109(3), 641-650. [More Information]
  • Cooper, W., Yu, B., Yip, P., Ng, C., Lum, T., Farzin, M., Trent, R., Mercorella, B., Clarkson, A., Kohonen-Corish, M., Horvath, L., Kench, J., McCaughan, B., Gill, A., O'Toole, S. (2013). EGFR mutant-specific immunohistochemistry has high specificity and sensitivity for detecting targeted activating EGFR mutations in lung adenocarcinoma. Journal of Clinical Pathology, 66(9), 744-748. [More Information]
  • Hulf, T., Sibbritt, T., Wiklund, E., Patterson, K., Song, J., Stirzaker, C., Qu, W., Nair, S., Horvath, L., Armstrong, N., et al (2013). Epigenetic-induced repression of microRNA-205 is associated with MED1 activation and a poorer prognosis in localized prostate cancer. Oncogene, 32(23), 2891-2899. [More Information]
  • Yip, P., Yu, B., Cooper, W., Selinger, C., Ng, C., Kennedy, C., Kohonen-Corish, M., McCaughan, B., Trent, R., Boyer, M., Kench, J., Horvath, L., O'Toole, S. (2013). Patterns of DNA mutations and ALK Rearrangement in Resected Node Negative Lung Adenocarcinoma. Journal of Thoracic Oncology, 8(4), 408-414. [More Information]
  • Selinger, C., Rogers, T., Russell, P., O'Toole, S., Yip, P., Wright, G., Wainer, Z., Horvath, L., Boyer, M., McCaughan, B., et al (2013). Testing for ALK rearrangement in lung adenocarcinoma: A multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Modern Pathology, 26(12), 1545-1553. [More Information]
  • Venkateswaran, L., Butow, P., Jansen, J., Wilcken, N., WONG, M., Hui, R., Szonyi, G., Gebski, V., Naganathan, V., Horvath, L., Tattersall, M. (2012). Decision making in older patients with advanced cancer: Does doctor know best? Medical Journal of Australia, 196(1), 35-39. [More Information]
  • Savdie, R., Horvath, L., Pe Benito, R., Rasiah, K., Haynes, A., Chatfield, M., Stricker, P., Turner, J., Delprado, W., Henshall, S., Kench, J., et al (2012). High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy. BJU International, 109(12), 1794-1800. [More Information]
  • Femia, J., Hardy, T., Spies, J., Horvath, L. (2012). Posterior reversible encephalopathy syndrome following chemotherapy with oxaliplatin and a fluoropyrimidine: A case report and literature review. Asia-Pacific Journal of Clinical Oncology, 8(2), 115-122. [More Information]
  • Randall, S., McKay, M., Pascovici, D., Mahon, K., Horvath, L., Clarke, S., Molloy, M. (2012). Remarkable temporal stability of high-abundance human plasma proteins assessed by targeted mass spectrometry. Proteomics - Clinical Applications, 6(11-12), 626-634. [More Information]
  • Goldstein, D., Spry, N., Cummins, M., Brown, C., van Hazel, G., Carroll, S., Selva-Nayagam, S., Borg, M., Ackland, S., Wratten, C., Hruby, G., Horvath, L., Gebski, V., et al (2012). The GOFURTGO Study: AGITG Phase II Study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer. British Journal of Cancer, 106(1), 61-69. [More Information]
  • Devaney, J., Stirzaker, C., Qu, W., Song, J., Statham, A., Patterson, K., Horvath, L., Tabor, B., Coolen, M., Hulf, T., Kench, J., et al (2011). Epigenetic Deregulation Across Chromosome 2q14.2 Differentiates Normal from Prostate Cancer and Provides a Regional Panel of Novel DNA Methylation Cancer Biomarkers. Cancer Epidemiology, Biomarkers and Prevention, 20(1), 148-159. [More Information]
  • Mahon, K., Henshall, S., Sutherland, R., Horvath, L. (2011). Pathways of chemotherapy resistance in castration-resistant prostate cancer. Endocrine-Related Cancer, 18(4), R103-R123. [More Information]
  • Kench, J., Clouston, D., Delprado, W., Eade, T., Ellis, D., Horvath, L., Samaratunga, H., Stahl, J., Stapleton, A., Egevad, L., et al (2011). Prognostic factors in prostate cancer. Key elements in structured histopathology reporting of radical prostatectomy specimens. Pathology, 43(5), 410-419. [More Information]
  • Leighl, N., Shepherd, H., Butow, P., Clarke, S., McJannett, M., Beale, P., Wilcken, N., Moore, M., Chen, E., Goldstein, D., Horvath, L., Tattersall, M., et al (2011). Supporting Treatment Decision Making in Advanced Cancer: A Randomized Trial of a Decision Aid for Patients With Advanced Colorectal Cancer Considering Chemotherapy. Journal of Clinical Oncology, 29(15), 2077-2084. [More Information]
  • Cooper, W., O'Toole, S., Boyer, M., Horvath, L., Mahar, A. (2011). What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements. Pathology, 43(2), 103-115. [More Information]
  • Ocean, A., Polite, B., Christos, P., Horvath, L., Hamilton, A., Matulich, D., Chen, H., Sparano, J., Kindler, H. (2010). Cetuximab is Associated with Excessive Toxicity when Combined with Bevacizumab Plus mFOLFOX6 in Metastatic Colorectal Carcinoma. Clinical Colorectal Cancer, 9(5), 290-296. [More Information]
  • Bianco-Miotto, T., Chiam, K., Buchanan, G., Jindal, S., Day, T., Thomas, M., Pickering, M., O'Loughlin, M., Ryan, N., Raymond, W., Horvath, L., Kench, J., et al (2010). Global Levels of Specific Histone Modifications and an Epigenetic Gene Signature Predict Prostate Cancer Progression and Development. Cancer Epidemiology, Biomarkers and Prevention, 19(10), 2611-2622. [More Information]
  • Balanathan, P., Williams, E., Wang, H., Pedersen, J., Horvath, L., Achen, M., Stacker, S., Risbridger, G. (2009). Elevated level of inhibin-alpha subunit is pro-tumourigenic and pro-metastatic and associated with extracapsular spread in advanced prostate cancer. British Journal of Cancer, 100(11), 1784-1793. [More Information]
  • Thanigasalam, R., Rasiah, K., Stricker, P., Haynes, A., Sutherland, S., Sutherland, R., Henshall, S., Horvath, L. (2009). Stage migration in localized prostate cancer has no effect on the post-radical prostatectomy Kattan nomogram. BJU International, 105(5), 642-647. [More Information]
  • Seng, T., Currey, N., Cooper, W., Lee, C., Chan, C., Sutherland, R., Horvath, L., Kennedy, C., McCaughan, B., Kohonen-Corish, M. (2008). DLEC1 and MLH1 promoter methylation are associated with poor prognosis in non-small cell lung carcinoma. British Journal of Cancer, 99(2), 375-382. [More Information]
  • Sakko, A., Butler, M., Byers, S., Reinboth, B., Stahl, J., Kench, J., Horvath, L., Sutherland, R., Stricker, P., Henshall, S., et al (2008). Immunohistochemical level of unsulfated chondroitin disaccharides in the cancer stroma is an independent predictor of prostate cancer relapse. Cancer Epidemiology, Biomarkers and Prevention, 17(9), 2488-2497. [More Information]
  • Sharma, R., Rivory, L., Beale, P., Ong, S., Horvath, L., Clarke, S. (2006). A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer. British Journal of Cancer, 94(7), 964-968. [More Information]
  • Rasiah, K., Kench, J., Gardiner-Garden, M., Biankin, A., Golovsky, D., Brenner, P., Kooner, R., O'Neill, G., Turner, J., Delprado, W., Lee, C., Horvath, L., et al (2006). Aberrant neuropeptide Y and macrophage inhibitory cytokine-1 expression are early events in prostate cancer development and are associated with poor prognosis. Cancer Epidemiology, Biomarkers and Prevention, 15(4), 711-716. [More Information]
  • Henshall, S., Horvath, L., Quinn, D., Eggleton, S., Grygiel, J., Stricker, P., Biankin, A., Kench, J., Sutherland, R. (2006). Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy. Journal of the National Cancer Institute, 98(19), 1420-1424. [More Information]
  • Read, J., Beale, P., Horvath, L., Volker, D., Childs, A., Smith, N., Clarke, S. (2005). Impact of fish-oil supplement on nutritional parameters, inflammation and chemotherapy induced toxicity in colorectal cancer (CRC) patients receiving FOLFIRI - A pilot study. Journal of Clinical Oncology, 23(16S (supplement)), Abstract 8243 S789-S789.
  • Horvath, L., Henshall, S., Lee, C., Kench, J., Golovsky, D., Brenner, P., O'Neill, G., Kooner, R., Stricker, P., Grygiel, J., et al (2005). Lower levels of nuclear beta-catenin predict for a poorer prognosis in localized prostate cancer. International Journal of Cancer, 113(3), 415-422. [More Information]

2014

  • Nagrial, A., Chang, D., Nguyen, N., Johns, A., Chantrill, L., Humphris, J., Chin, V., Samra, J., Gill, A., Pajic, M., Kench, J., et al (2014). Adjuvant chemotherapy in elderly patients with pancreatic cancer. British Journal of Cancer, 110(2), 313-319. [More Information]
  • Suttie, C., Hruby, G., Horvath, L., Thompson, J. (2014). Cardiac metastasis in Merkel cell carcinoma. Journal of Clinical Oncology, 32(13), e52-e53. [More Information]
  • Lin, H., Castillo, L., Mahon, K., Chiam, K., Lee, B., Nguyen, Q., Boyer, M., Stockler, M., Pavlakis, N., Marx, G., Gurney, H., Horvath, L., et al (2014). Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer. British Journal of Cancer, 110(10), 2462-2471. [More Information]
  • Sutherland, S., Pe Benito, R., Henshall, S., Horvath, L., Kench, J. (2014). Expression of phosphorylated-mTOR during the development of prostate cancer. The Prostate, 74(12), 1231-1239. [More Information]
  • Yip, P., Cooper, W., Kohonen-Corish, M., Lin, B., McCaughan, B., Boyer, M., Kench, J., Horvath, L. (2014). Phosphorylated Akt expression is a prognostic marker in early-stage non-small cell lung cancer. Journal of Clinical Pathology, 67(4), 333-340. [More Information]

2013

  • Selth, L., Townley, S., Bert, A., Stricker, P., Sutherland, P., Horvath, L., Goodall, G., Butler, L., Tilley, W. (2013). Circulating microRNAs predict biochemical recurrence in prostate cancer patients. British Journal of Cancer, 109(3), 641-650. [More Information]
  • Cooper, W., Yu, B., Yip, P., Ng, C., Lum, T., Farzin, M., Trent, R., Mercorella, B., Clarkson, A., Kohonen-Corish, M., Horvath, L., Kench, J., McCaughan, B., Gill, A., O'Toole, S. (2013). EGFR mutant-specific immunohistochemistry has high specificity and sensitivity for detecting targeted activating EGFR mutations in lung adenocarcinoma. Journal of Clinical Pathology, 66(9), 744-748. [More Information]
  • Hulf, T., Sibbritt, T., Wiklund, E., Patterson, K., Song, J., Stirzaker, C., Qu, W., Nair, S., Horvath, L., Armstrong, N., et al (2013). Epigenetic-induced repression of microRNA-205 is associated with MED1 activation and a poorer prognosis in localized prostate cancer. Oncogene, 32(23), 2891-2899. [More Information]
  • Yip, P., Yu, B., Cooper, W., Selinger, C., Ng, C., Kennedy, C., Kohonen-Corish, M., McCaughan, B., Trent, R., Boyer, M., Kench, J., Horvath, L., O'Toole, S. (2013). Patterns of DNA mutations and ALK Rearrangement in Resected Node Negative Lung Adenocarcinoma. Journal of Thoracic Oncology, 8(4), 408-414. [More Information]
  • Selinger, C., Rogers, T., Russell, P., O'Toole, S., Yip, P., Wright, G., Wainer, Z., Horvath, L., Boyer, M., McCaughan, B., et al (2013). Testing for ALK rearrangement in lung adenocarcinoma: A multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Modern Pathology, 26(12), 1545-1553. [More Information]

2012

  • Venkateswaran, L., Butow, P., Jansen, J., Wilcken, N., WONG, M., Hui, R., Szonyi, G., Gebski, V., Naganathan, V., Horvath, L., Tattersall, M. (2012). Decision making in older patients with advanced cancer: Does doctor know best? Medical Journal of Australia, 196(1), 35-39. [More Information]
  • Savdie, R., Horvath, L., Pe Benito, R., Rasiah, K., Haynes, A., Chatfield, M., Stricker, P., Turner, J., Delprado, W., Henshall, S., Kench, J., et al (2012). High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy. BJU International, 109(12), 1794-1800. [More Information]
  • Femia, J., Hardy, T., Spies, J., Horvath, L. (2012). Posterior reversible encephalopathy syndrome following chemotherapy with oxaliplatin and a fluoropyrimidine: A case report and literature review. Asia-Pacific Journal of Clinical Oncology, 8(2), 115-122. [More Information]
  • Randall, S., McKay, M., Pascovici, D., Mahon, K., Horvath, L., Clarke, S., Molloy, M. (2012). Remarkable temporal stability of high-abundance human plasma proteins assessed by targeted mass spectrometry. Proteomics - Clinical Applications, 6(11-12), 626-634. [More Information]
  • Goldstein, D., Spry, N., Cummins, M., Brown, C., van Hazel, G., Carroll, S., Selva-Nayagam, S., Borg, M., Ackland, S., Wratten, C., Hruby, G., Horvath, L., Gebski, V., et al (2012). The GOFURTGO Study: AGITG Phase II Study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer. British Journal of Cancer, 106(1), 61-69. [More Information]

2011

  • Devaney, J., Stirzaker, C., Qu, W., Song, J., Statham, A., Patterson, K., Horvath, L., Tabor, B., Coolen, M., Hulf, T., Kench, J., et al (2011). Epigenetic Deregulation Across Chromosome 2q14.2 Differentiates Normal from Prostate Cancer and Provides a Regional Panel of Novel DNA Methylation Cancer Biomarkers. Cancer Epidemiology, Biomarkers and Prevention, 20(1), 148-159. [More Information]
  • Mahon, K., Henshall, S., Sutherland, R., Horvath, L. (2011). Pathways of chemotherapy resistance in castration-resistant prostate cancer. Endocrine-Related Cancer, 18(4), R103-R123. [More Information]
  • Kench, J., Clouston, D., Delprado, W., Eade, T., Ellis, D., Horvath, L., Samaratunga, H., Stahl, J., Stapleton, A., Egevad, L., et al (2011). Prognostic factors in prostate cancer. Key elements in structured histopathology reporting of radical prostatectomy specimens. Pathology, 43(5), 410-419. [More Information]
  • Leighl, N., Shepherd, H., Butow, P., Clarke, S., McJannett, M., Beale, P., Wilcken, N., Moore, M., Chen, E., Goldstein, D., Horvath, L., Tattersall, M., et al (2011). Supporting Treatment Decision Making in Advanced Cancer: A Randomized Trial of a Decision Aid for Patients With Advanced Colorectal Cancer Considering Chemotherapy. Journal of Clinical Oncology, 29(15), 2077-2084. [More Information]
  • Cooper, W., O'Toole, S., Boyer, M., Horvath, L., Mahar, A. (2011). What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements. Pathology, 43(2), 103-115. [More Information]

2010

  • Ocean, A., Polite, B., Christos, P., Horvath, L., Hamilton, A., Matulich, D., Chen, H., Sparano, J., Kindler, H. (2010). Cetuximab is Associated with Excessive Toxicity when Combined with Bevacizumab Plus mFOLFOX6 in Metastatic Colorectal Carcinoma. Clinical Colorectal Cancer, 9(5), 290-296. [More Information]
  • Bianco-Miotto, T., Chiam, K., Buchanan, G., Jindal, S., Day, T., Thomas, M., Pickering, M., O'Loughlin, M., Ryan, N., Raymond, W., Horvath, L., Kench, J., et al (2010). Global Levels of Specific Histone Modifications and an Epigenetic Gene Signature Predict Prostate Cancer Progression and Development. Cancer Epidemiology, Biomarkers and Prevention, 19(10), 2611-2622. [More Information]

2009

  • Balanathan, P., Williams, E., Wang, H., Pedersen, J., Horvath, L., Achen, M., Stacker, S., Risbridger, G. (2009). Elevated level of inhibin-alpha subunit is pro-tumourigenic and pro-metastatic and associated with extracapsular spread in advanced prostate cancer. British Journal of Cancer, 100(11), 1784-1793. [More Information]
  • Thanigasalam, R., Rasiah, K., Stricker, P., Haynes, A., Sutherland, S., Sutherland, R., Henshall, S., Horvath, L. (2009). Stage migration in localized prostate cancer has no effect on the post-radical prostatectomy Kattan nomogram. BJU International, 105(5), 642-647. [More Information]

2008

  • Seng, T., Currey, N., Cooper, W., Lee, C., Chan, C., Sutherland, R., Horvath, L., Kennedy, C., McCaughan, B., Kohonen-Corish, M. (2008). DLEC1 and MLH1 promoter methylation are associated with poor prognosis in non-small cell lung carcinoma. British Journal of Cancer, 99(2), 375-382. [More Information]
  • Sakko, A., Butler, M., Byers, S., Reinboth, B., Stahl, J., Kench, J., Horvath, L., Sutherland, R., Stricker, P., Henshall, S., et al (2008). Immunohistochemical level of unsulfated chondroitin disaccharides in the cancer stroma is an independent predictor of prostate cancer relapse. Cancer Epidemiology, Biomarkers and Prevention, 17(9), 2488-2497. [More Information]

2006

  • Sharma, R., Rivory, L., Beale, P., Ong, S., Horvath, L., Clarke, S. (2006). A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer. British Journal of Cancer, 94(7), 964-968. [More Information]
  • Rasiah, K., Kench, J., Gardiner-Garden, M., Biankin, A., Golovsky, D., Brenner, P., Kooner, R., O'Neill, G., Turner, J., Delprado, W., Lee, C., Horvath, L., et al (2006). Aberrant neuropeptide Y and macrophage inhibitory cytokine-1 expression are early events in prostate cancer development and are associated with poor prognosis. Cancer Epidemiology, Biomarkers and Prevention, 15(4), 711-716. [More Information]
  • Henshall, S., Horvath, L., Quinn, D., Eggleton, S., Grygiel, J., Stricker, P., Biankin, A., Kench, J., Sutherland, R. (2006). Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy. Journal of the National Cancer Institute, 98(19), 1420-1424. [More Information]

2005

  • Read, J., Beale, P., Horvath, L., Volker, D., Childs, A., Smith, N., Clarke, S. (2005). Impact of fish-oil supplement on nutritional parameters, inflammation and chemotherapy induced toxicity in colorectal cancer (CRC) patients receiving FOLFIRI - A pilot study. Journal of Clinical Oncology, 23(16S (supplement)), Abstract 8243 S789-S789.
  • Horvath, L., Henshall, S., Lee, C., Kench, J., Golovsky, D., Brenner, P., O'Neill, G., Kooner, R., Stricker, P., Grygiel, J., et al (2005). Lower levels of nuclear beta-catenin predict for a poorer prognosis in localized prostate cancer. International Journal of Cancer, 113(3), 415-422. [More Information]

To update your profile click here. For support on your academic profile contact .